Frontiers in Pharmacology
Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database
Study of 42,941 peoplePopulations
General disorders and administration site conditions
Papers on general disorders and administration site conditions
4 papers
Friday, September 11
Wednesday, November 6
Frontiers in Pharmacology
Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups
Study of 37,827 peopleTirzepatide
Tuesday, December 13
Frontiers in Pharmacology
Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
Study in peoplePCSK9 inhibitors